Tuesday, March 28, 2023 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Class Action

SAN DIEGO - Ardea Biosciences is selling itself too cheaply through an unfair process to Astrazeneca, for $32 a share or $1.26 billion, shareholders say in a class action in Superior Court.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.